Measurement of health-related quality of life during chemotherapy – the importance of timing

References

• Claassens L, van Meerbeeck J, Coens C, et al. Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol. 2011;29:2104–2120.
   PubMed Web of Science ®Google Scholar
• Saad ED, Adamowicz K, Katz A, et al. Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials. Cancer Treat Rev. 2012;38:807–814.
   PubMed Web of Science ®Google Scholar
• Bottomley A. The cancer patient and quality of life. Oncologist. 2002;7:120–125.
   PubMed Web of Science ®Google Scholar
• Au HJ, Ringash J, Brundage M, et al. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev Pharmacoecon Outcomes Res. 2010;10:119–128.
   PubMed Web of Science ®Google Scholar
• Ediebah DE, Coens C, Maringwa JT, et al. Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients. Ann Oncol. 2013;24:231–237.
   PubMed Web of Science ®Google Scholar
• Fayers P. MRC quality of life studies using a daily diary card-practical lessons learned from cancer trials. Qual Life Res. 1995;4:343–352.
   PubMed Web of Science ®Google Scholar
• Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol. 2005;23:142–153.
   PubMed Web of Science ®Google Scholar
• Giesinger JM, Wintner LM, Zabernigg A, et al. Assessing quality of life on the day of chemotherapy administration underestimates patients’ true symptom burden. BMC Cancer. 2014;14:758.
   PubMed Web of Science ®Google Scholar
• Flotten O, Gronberg BH, Bremnes R, et al. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012;107:442–447.
   PubMed Web of Science ®Google Scholar
• Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:3217–3224.
   PubMed Web of Science ®Google Scholar
• Helbekkmo N, Sundstrom SH, Aasebo U, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer. 2007;97:283–289.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376.
   PubMed Web of Science ®Google Scholar
• Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 1994;30a:635–642.
   PubMed Web of Science ®Google Scholar
• Damm K, Roeske N, Jacob C. Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. Health Econ Rev. 2013;3:15.
   PubMedGoogle Scholar
• Fayers PM, Aaronson N, Bjordal K. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
   Google Scholar
• Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–144.
   PubMed Web of Science ®Google Scholar
• Fayers P, Machin D. Quality of life: the assessment, analysis and interpretation of patient-reported outcomes. Chichester: John Wiley & Sons; 2007.
   Google Scholar
• Fayers PM, Bleehen NM, Girling DJ, et al. Assessment of quality of life in small-cell lung cancer using a daily diary card developed by the Medical Research Council lung cancer working party. Br J Cancer. 1991;64:299–306.
   PubMed Web of Science ®Google Scholar
• Curran D, Molenberghs G, Fayers PM, et al. Incomplete quality of life data in randomized trials: missing forms. Statist Med. 1998;17:697–709.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JF, Vandebroek JE, Nackaerts KL, et al. Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol. 2001;12:1221–1230.
   PubMed Web of Science ®Google Scholar
• Crino L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol. 2008;26:4253–4260.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:3025–3034.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Gallo C, Ceribelli A, et al. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol. 2007;8:500–512.
   PubMed Web of Science ®Google Scholar